SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-20-026469
Filing Date
2020-09-14
Accepted
2020-09-14 16:31:56
Documents
6
Period of Report
2020-09-01
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea126804-8k_aditxtherap.htm 8-K 38609
2 UNDERWRITING AGREEMENT, DATED SEPTEMBER 1, 2020 ea126804ex1-1_aditxtherap.htm EX-1.1 234005
3 SERIES A-1 WARRANT AGENT AGREEMENT, INCLUDING FORM OF SERIES A-1 WARRANT, DATED ea126804ex10-1_aditxtherap.htm EX-10.1 117226
4 SERIES B-1 WARRANT AGENT AGREEMENT, INCLUDING FORM OF SERIES B-1 WARRANT, DATED ea126804ex10-2_aditxtherap.htm EX-10.2 143471
5 PRESS RELEASE DATED SEPTEMBER 1, 2020 ea126804ex99-1_aditxtherap.htm EX-99.1 13228
6 PRESS RELEASE DATED SEPTEMBER 10, 2020 ea126804ex99-2_aditxtherap.htm EX-99.2 13973
  Complete submission text file 0001213900-20-026469.txt   561697
Mailing Address 11161 ANDERSON STREET SUITE 105-10014 LOMA LINDA CA 92354
Business Address 11161 ANDERSON STREET SUITE 105-10014 LOMA LINDA CA 92354 909-488-0844
ADiTx Therapeutics, Inc. (Filer) CIK: 0001726711 (see all company filings)

IRS No.: 823204328 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39336 | Film No.: 201173490
SIC: 2834 Pharmaceutical Preparations